HALOZYME THERAPEUT revenue breakdown overview

HALOZYME THERAPEUT revenue for the last year amounted to 698.18 M CHF, the most of which — 698.18 M CHF — came from its highest performing source at the moment, Enzymes and Devices, the year earlier bringing 610.43 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought HALOZYME THERAPEUT 494.38 M CHF, and the year before that — 405.02 M CHF.